Grace Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Grace Therapeutics, Inc. (GRCE) reported Diluted Shares Outstanding (Weighted Average) of 17.27 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-13
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 17.27M shares, a 8.45% increase year-over-year.
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 17.26M shares, a 24.77% increase year-over-year.
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 16.93M shares, a 47.17% increase year-over-year.
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 15.92M shares, a 38.40% increase year-over-year.
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2026 was 16.51M shares, a 36.60% increase from fiscal 2025.
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 12.09M shares, a 26.85% increase from fiscal 2024.
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 9.53M shares, a 28.16% increase from fiscal 2023.
- Grace Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 7.44M shares, a 79.82% decline from fiscal 2022.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 17.27M shares 10-Q · filed 2026-08-13 | 17.26M shares derived: average of 2 quarters · filed 2026-08-13 | 17.15M shares derived: average of 3 quarters · filed 2026-08-13 | 16.85M shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | 17.26M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | 17.09M shares derived: average of 2 quarters · filed 2026-06-18 | 16.70M shares derived: average of 3 quarters · filed 2026-06-18 | 16.51M shares 10-K · filed 2026-06-18 | ||||
| 2025-12-31 | 16.93M shares 10-Q · filed 2026-02-12 | 16.43M shares derived: average of 2 quarters · filed 2026-02-12 | 16.26M shares 10-Q · filed 2026-02-12 | 15.65M shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-09-30 | 15.92M shares 10-Q · filed 2025-11-13 | 15.92M shares 10-Q · filed 2025-11-13 | 15.23M shares derived: average of 3 quarters · filed 2026-08-13 | 14.30M shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | 15.92M shares 10-Q · filed 2026-08-13 | 14.88M shares derived: average of 2 quarters · filed 2026-08-13 | 13.75M shares derived: average of 3 quarters · filed 2026-08-13 | 13.19M shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | 13.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-18 | 12.67M shares derived: average of 2 quarters · filed 2026-06-18 | 12.28M shares derived: average of 3 quarters · filed 2026-06-18 | 12.09M shares 10-K · filed 2026-06-18 | ||||
| 2024-12-31 | 11.51M shares 10-Q · filed 2026-02-12 | 11.51M shares derived: average of 2 quarters · filed 2026-02-12 | 11.51M shares 10-Q · filed 2026-02-12 | 11.36M shares derived: average of 4 quarters · filed 2026-02-12 | ||||
| 2024-09-30 | 11.51M shares 10-Q · filed 2025-11-13 | 11.51M shares 10-Q · filed 2025-11-13 | 11.31M shares derived: average of 3 quarters · filed 2025-11-13 | 11.36M shares derived: average of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | 10.93M shares 10-Q · filed 2025-08-12 | 11.21M shares derived: average of 2 quarters · filed 2025-08-12 | 11.31M shares derived: average of 3 quarters · filed 2025-08-12 | 10.37M shares derived: average of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | 11.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | 11.50M shares derived: average of 2 quarters · filed 2025-06-23 | 10.18M shares derived: average of 3 quarters · filed 2025-06-23 | 9.53M shares 10-K · filed 2025-06-23 | ||||
| 2023-12-31 | 11.51M shares 10-Q · filed 2025-02-13 | 9.53M shares derived: average of 2 quarters · filed 2025-02-13 | 8.87M shares 10-Q · filed 2025-02-13 | 8.50M shares derived: average of 4 quarters · filed 2025-02-13 | ||||
| 2023-09-30 | 7.55M shares 10-Q · filed 2024-11-13 | 7.49M shares 10-Q · filed 2024-11-13 | 7.49M shares derived: average of 3 quarters · filed 2024-11-13 | 7.48M shares derived: average of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | 7.44M shares 10-Q · filed 2024-08-09 | 7.46M shares derived: average of 2 quarters · filed 2024-08-09 | 7.45M shares derived: average of 3 quarters · filed 2024-08-09 | 7.45M shares derived: average of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | 7.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-21 | 7.46M shares derived: average of 2 quarters · filed 2024-06-21 | 7.45M shares derived: average of 3 quarters · filed 2024-06-21 | 7.44M shares 10-K · filed 2024-06-21 | 44.61M shares 10-K · filed 2023-06-23 | |||
| 2022-12-31 | 7.44M shares 10-Q · filed 2024-02-12 | 44.61M shares 10-Q · filed 2023-02-14 | 7.43M shares derived: average of 2 quarters · filed 2024-02-12 | 7.42M shares 10-Q · filed 2024-02-12 | 44.50M shares 10-Q · filed 2023-02-14 | 23.06M shares derived: average of 4 quarters · filed 2024-02-12 | ||
| 2022-09-30 | 7.43M shares 10-Q · filed 2023-11-13 | 44.55M shares 10-Q · filed 2022-11-14 | 7.41M shares 10-Q · filed 2023-11-13 | 44.44M shares 10-Q · filed 2022-11-14 | 28.27M shares derived: average of 3 quarters · filed 2023-11-13 | 32.28M shares derived: average of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | 7.39M shares 10-Q · filed 2023-08-11 | 44.33M shares 10-Q · filed 2022-08-11 | 38.70M shares derived: average of 2 quarters · filed 2023-08-11 | 40.56M shares derived: average of 3 quarters · filed 2023-08-11 | 38.62M shares derived: average of 4 quarters · filed 2023-08-11 | |||
| 2022-03-31 | 70.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-23 | 57.15M shares derived: average of 2 quarters · filed 2023-06-23 | 49.03M shares derived: average of 3 quarters · filed 2023-06-23 | 36.84M shares 10-K · filed 2023-06-23 | ||||
| 2021-12-31 | 44.29M shares 10-Q · filed 2023-02-14 | 38.54M shares derived: average of 2 quarters · filed 2023-02-14 | 25.79M shares 10-Q · filed 2023-02-14 | |||||
| 2021-09-30 | 32.79M shares 10-Q · filed 2022-11-14 | 29.44M shares 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | 26.05M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |